Abstract: An example method for quantitatively predicting a cancer patient's response to immune-based or targeted therapy is described herein. The method can include receiving patient data for the cancer patient. The patient data is derived from a blood or tissue sample. The method can also include clustering a plurality of immune cell phenotypes present in the patient data, and generating a plurality of violin plots of signal intensity for at least one of the immune cell phenotypes. The clustered patient data can include a plurality of nodes, and each of the violin plots can capture a number of events. The method can further include statistically analyzing the violin plots to predict the cancer patient's response to immune-based or targeted therapy.

Abstract: Compounds that bind S100 and inhibit the S100-p53 protein-protein interaction and activate the tumor suppressor activity of p53, and thus which have an antineoplastic effect are disclosed, as well as methods for identifying these compounds, compositions comprising the same, and methods of using the same to treat cancer.

Abstract: Compounds that bind S100 and inhibit the S100-p53 protein-protein interaction and activate the tumor suppressor activity of p53, and thus which have an antineoplastic effect are disclosed, as well as methods for identifying these compounds, compositions comprising the same, and methods of using the same to treat cancer.

Abstract: Compounds that bind S100 and inhibit the S100-p53 protein-protein interaction and activate the tumor suppressor activity of p53, and thus which have an antineoplastic effect are disclosed, as well as methods for identifying these compounds, compositions comprising the same, and methods of using the same to treat cancer.